UiPath (NYSE: PATH), the New York‑based leader in enterprise automation, released its fourth‑quarter and full‑year fiscal 2026 results on Thursday. The company reported a GAAP operating profit of $57 million for the year, marking the first time it has posted a profit on a GAAP basis since going public. Revenue climbed 13 % year‑over‑year to $1.611 billion, while annual recurring revenue (ARR) reached $1.853 billion, up 11 % from the prior year. The numbers come alongside a $500 million stock repurchase authorization that follows the completion of a previous $1 billion buy‑back program.
For the fourth quarter ending January 31, 2026, UiPath posted $481 million in revenue, a 14 % increase versus the same period a year earlier. The quarter’s GAAP operating income was $80 million, and non‑GAAP operating income stood at $150 million. Net cash generated from operations hit $182 million, and the firm’s cash, cash equivalents, and marketable securities totaled $1.69 billion at quarter‑end.
On a full‑year basis, the company’s revenue rose to $1.611 billion, driven by $186 million of net new ARR. GAAP gross margin held at 83 % and non‑GAAP gross margin at 85 %. GAAP operating income reached $57 million, while non‑GAAP operating income was $370 million. Operating cash flow for the year was $371 million, and non‑GAAP adjusted free cash flow was $372 million.
“We delivered a strong quarter and closed out a year of disciplined execution, with ARR growing 11 % year‑over‑year to $1.853 billion,” said Daniel Dines, UiPath founder and chief executive officer. “As enterprise AI adoption moves from experimentation to scaled deployment, customers increasingly need a platform that can execute complex processes with reliability, governance, and scale. By bringing deterministic automation, agentic AI, and enterprise‑grade orchestration together on a single platform, UiPath provides the execution layer enterprises trust to run mission‑critical processes in the agentic era.”
Chief operating officer and chief financial officer Ashim Gupta added, “I am pleased with our fourth‑quarter results and the operational progress we achieved throughout the year, including reaching full‑year GAAP profitability for the first time in company history. The operating discipline we built throughout the year is translating into more consistent execution and expanding operating leverage. As we enter fiscal 2027, we remain focused on expanding adoption across our platform and driving continued operating discipline as we scale the business.”
Share‑repurchase update
Earlier this month, UiPath confirmed that it had exhausted its prior $1 billion stock repurchase program. The board subsequently approved a fresh authorization to buy back up to $500 million of Class A common stock. The repurchases will be carried out opportunistically, using:
- open‑market purchases
- private transactions
- Rule 10b5‑1 trading plans
- Rule 10b‑18‑compliant methods
depending on market conditions and the company’s cash position.
Outlook for fiscal 2027
UiPath projected first‑quarter fiscal 2027 revenue between $395 million and $400 million, with ARR expected to sit between $1.894 billion and $1.899 billion as of April 30, 2026. Non‑GAAP operating income for the quarter is forecast at roughly $80 million. For the full fiscal year, the firm anticipates revenue in the $1.754 billion‑$1.759 billion range and ARR of $2.051 billion‑$2.056 billion as of January 31, 2027.
Non‑GAAP operating‑income guidance caveat
The company disclosed that reconciling its non‑GAAP operating‑income guidance to a comparable GAAP measure would require “unreasonable efforts” because of the high variability and low visibility of the excluded items—chiefly the impact of stock‑based compensation tied to fluctuating share prices. UiPath cautioned that these fluctuations could cause a “significant, and potentially unpredictable, impact on our future GAAP financial results.”
Recent product and strategic moves
Agentic AI for healthcare
UiPath unveiled a suite of agentic AI applications aimed at the healthcare sector. The new tools target medical‑record summarization, claim‑denial prevention and resolution, and prior‑authorization workflows. By integrating data‑connectivity, process‑automation, and purpose‑built AI agents, the solutions are designed to reduce manual effort, accelerate revenue‑cycle management, and improve compliance in a highly regulated environment.
WorkFusion acquisition
In a move that deepens its foothold in financial‑crime compliance, UiPath announced the acquisition of WorkFusion, a company known for AI‑driven agents that detect money‑laundering, fraud, and other illicit activities. The deal expands UiPath’s portfolio of industry‑specific, AI‑powered automation for banking and financial services, positioning the combined entity to address end‑to‑end compliance workflows that traditionally rely on siloed, manual processes.
Veeva AI Partner Program
UiPath joined Veeva’s AI Partner Program to bring agentic testing capabilities to the life‑sciences market. The collaboration promises end‑to‑end workflows that streamline computer‑software assurance and validation for quality‑management processes. While details remain limited, the partnership signals UiPath’s intent to embed its automation engine deeper into regulated life‑science environments, where rigorous testing and documentation are mandatory.
Market context
UiPath’s return to GAAP profitability arrives at a pivotal moment for the broader robotic‑process‑automation (RPA) industry. Competitors such as Automation Anywhere and Blue Prism have also been pivoting toward AI‑enhanced automation, often described as “hyper‑automation” or “agentic automation.” UiPath’s emphasis on deterministic automation combined with generative AI agents differentiates its platform from pure‑rule‑based RPA tools, potentially giving it an edge in complex, data‑intensive use cases.
The company’s ARR growth, though modest at 11 % year‑over‑year, reflects a market that is transitioning from pilot projects to production‑grade deployments. Enterprises are increasingly looking for platforms that can handle end‑to‑end orchestration, governance, and AI integration—all of which UiPath highlights in its product roadmap.
Financially, the $500 million buy‑back underscores confidence in the firm’s balance sheet and a belief that the stock is undervalued relative to its cash position. With $1.69 billion in liquid assets, UiPath can afford both shareholder returns and continued investment in product development and acquisitions.
Analysts have noted that the non‑GAAP operating‑income guidance of approximately $415 million for fiscal 2027 suggests a comfortable margin cushion, even after accounting for the variability of stock‑based compensation. The company’s caution about reconciling non‑GAAP figures to GAAP indicates a conservative approach to forward‑looking guidance, which may help manage investor expectations in a volatile tech‑stock environment.
What this means for customers
For organizations already leveraging UiPath’s automation platform, the earnings beat and GAAP profitability signal a maturing business model that can sustain long‑term product investment. The new healthcare AI tools could accelerate adoption in hospitals and payer networks, where manual claim processing still dominates. Meanwhile, the WorkFusion acquisition expands the suite of compliance‑focused bots, a critical need for banks facing heightened regulatory scrutiny after a wave of high‑profile money‑laundering scandals.
The partnership with Veeva also hints at deeper integration into life‑science quality‑management systems, an area where automation can dramatically reduce time‑to‑market for new drugs and devices. Enterprises that have been hesitant to adopt RPA due to compliance concerns may find the combined UiPath‑Veeva offering a compelling pathway.
Outlook for the automation sector
UiPath’s results reinforce the notion that the automation market is moving beyond cost‑center projects into revenue‑generating initiatives. As AI models become more capable of handling unstructured data, the line between traditional RPA and “agentic” AI blurs, creating opportunities for vendors that can deliver both deterministic workflows and adaptive, learning‑based agents.
The company’s guidance suggests a steady, if not explosive, growth trajectory for FY 2027. Revenue is expected to stay in the $1.75 billion‑$1.76 billion band, while ARR should cross the $2 billion threshold. If UiPath can sustain its operating leverage and continue to expand its AI‑driven portfolio, it may further solidify its position as the de‑facto platform for enterprise automation.
Get in touch with our Adtech experts
